Candice Jamois

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Chronic Lymphocytic Leukemia

Patient Reported Outcomes

Placebo Controlled

Top Venues

British journal of clinical pharmacology

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Sebastien Benzekry, Mélanie Karlsen, Célestin Bigarré, Abdessamad El Kaoutari, Bruno Gomes, Martin Stern, Ales Neubert, René Bruno, Francois Mercier, Suresh Vatakuti, Peter Curle, Candice Jamois
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic Biomarkers. Clinical pharmacology and therapeutics (2024)
John O Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El-Galaly, Aaron T Gerds, Vikas K Gupta, Brian Higgins, Kathrin Wonde, Candice Jamois, Bruno Kovic, Ling-Yuh Huw, Sudhakar Katakam, Margherita Maffioli, Ruben A Mesa, Jeanne Palmer, Marta Bellini, David Morrall Ross, Alessandro Maria Maria Vannucchi, Abdulraheem Yacoub
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood advances 6 (4) (2022)
Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Denis Sahin, Guillaume Cartron, Robert Marcus, Wolfgang Hiddemann, John F Seymour, Jonathan C Strefford, Chantal E Hargreaves, Georgina Meneses-Lorente, Nicolas Frey, Günter Fingerle-Rowson
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. British journal of clinical pharmacology 85 (7) (2019)
Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Nicolas Frey, Michael Brewster, Günter Fingerle-Rowson, Candice Jamois
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. British journal of clinical pharmacology 85 (9) (2019)